Axogen Inc vs Sibanye Stillwater Ltd — how do they compare? Axogen Inc trades at $38.97 (market cap $2.06B), while Sibanye Stillwater Ltd trades at $8.63 (market cap $6.03B). The key difference: Sibanye Stillwater Ltd is far larger — about 2.9× Axogen Inc's market cap, and Sibanye Stillwater Ltd pays a 3.63% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | SBSW | |
|---|---|---|
Market Cap | $2.06B | $6.03B |
Sector | Technology | Basic Materials |
52-Week High | $46.19 | $21.12 |
52-Week Low | $11.28 | $7.27 |
Enterprise Value | $1.98B | $7.66B |
Dividend Yield | — | 3.63% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
Sibanye Stillwater (SBSW) trades at $8.42, down 1.52% with bearish technical signals. The company shows mixed fundamentals with a negative net income margin of -3.99% and ROE of -12.38% for 2024, though revenue has stabilized at $112.13B. Recent news highlights a turnaround narrative with EBITDA growth and debt reduction plans. Technical indicators show bearish momentum with support at $8 and resistance at $9.
The stock presents a high-risk opportunity with significant upside to the $14.25 consensus price target. Key risks include persistent negative profitability, high debt levels, and commodity price volatility. Analyst sentiment is cautiously optimistic with 43% buy ratings, but investors should weigh the turnaround potential against ongoing operational challenges.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →